Cefpodoxime

Cefpodoxime

File:Cefpodoxime.svg
Clinical data
Pregnancy category	AU: B1 US: B (No risk in non-human studies)
Routes of administration	Oral
ATC code	J01DD13 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	50%
Protein binding	21% to 29%
Metabolism	Negligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Elimination half-life	2 hours
Excretion	Renal, unchanged
Identifiers
IUPAC name (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)- 2-methoxyimino-acetyl]amino}-3-(methoxymethyl)- 8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid
CAS Number	82619-04-3
PubChem CID	6335986
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H17N5O6S2
Molar mass	427.458 g/mol

WikiDoc Resources for Cefpodoxime
Articles
Most recent articles on Cefpodoxime Most cited articles on Cefpodoxime Review articles on Cefpodoxime Articles on Cefpodoxime in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefpodoxime Images of Cefpodoxime Photos of Cefpodoxime Podcasts & MP3s on Cefpodoxime Videos on Cefpodoxime
Evidence Based Medicine
Cochrane Collaboration on Cefpodoxime Bandolier on Cefpodoxime TRIP on Cefpodoxime
Clinical Trials
Ongoing Trials on Cefpodoxime at Clinical Trials.gov Trial results on Cefpodoxime Clinical Trials on Cefpodoxime at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefpodoxime NICE Guidance on Cefpodoxime NHS PRODIGY Guidance FDA on Cefpodoxime CDC on Cefpodoxime
Books
Books on Cefpodoxime
News
Cefpodoxime in the news Be alerted to news on Cefpodoxime News trends on Cefpodoxime
Commentary
Blogs on Cefpodoxime
Definitions
Definitions of Cefpodoxime
Patient Resources / Community
Patient resources on Cefpodoxime Discussion groups on Cefpodoxime Patient Handouts on Cefpodoxime Directions to Hospitals Treating Cefpodoxime Risk calculators and risk factors for Cefpodoxime
Healthcare Provider Resources
Symptoms of Cefpodoxime Causes & Risk Factors for Cefpodoxime Diagnostic studies for Cefpodoxime Treatment of Cefpodoxime
Continuing Medical Education (CME)
CME Programs on Cefpodoxime
International
Cefpodoxime en Espanol Cefpodoxime en Francais
Business
Cefpodoxime in the Marketplace Patents on Cefpodoxime
Experimental / Informatics
List of terms related to Cefpodoxime

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Cefpodoxime (marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin®) is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment. Pfizer, the parent company of Pharmacia & Upjohn, markets Cefpodoxime proxetil under the trade name Simplicef® for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as Banan®.

File:Cefpodoxime proxetil.svg

Structural formula of cefpodoxime proxetil

External links

• Template:PubChem - cefpodoxime proxetil
• Vantin Tablets and Oral Suspension Full U.S. Prescribing Information (from manufacturer's website)
• Simplicef (from manufacturer's website)